LDLR and PF4

Data Source:
BioGRID (pull down)
HPRD (in vivo)

		LDLR	PF4
Description		low density lipoprotein receptor	platelet factor 4
Image
GO Annotations	Cellular Component	Lysosome Early Endosome Late Endosome Golgi Apparatus Plasma Membrane Integral Component Of Plasma Membrane Clathrin-coated Pit External Side Of Plasma Membrane Cell Surface Endosome Membrane Membrane Basolateral Plasma Membrane Clathrin-coated Endocytic Vesicle Membrane Low-density Lipoprotein Particle Endolysosome Membrane Receptor Complex Apical Part Of Cell PCSK9-LDLR Complex	Extracellular Region Extracellular Space Cytoplasm Symbiont-containing Vacuole Membrane Platelet Alpha Granule Lumen Collagen-containing Extracellular Matrix
	Molecular Function	Amyloid-beta Binding Virus Receptor Activity Protease Binding Low-density Lipoprotein Particle Receptor Activity Calcium Ion Binding Protein Binding Low-density Lipoprotein Particle Binding Very-low-density Lipoprotein Particle Receptor Activity Clathrin Heavy Chain Binding Identical Protein Binding	Protein Binding Chemokine Activity Heparin Binding CXCR Chemokine Receptor Binding CXCR3 Chemokine Receptor Binding
	Biological Process	Lipid Metabolic Process Endocytosis Receptor-mediated Endocytosis Phagocytosis Long-term Memory Cholesterol Metabolic Process Positive Regulation Of Triglyceride Biosynthetic Process Regulation Of Phosphatidylcholine Catabolic Process Phospholipid Transport Intestinal Cholesterol Absorption Cholesterol Transport Plasma Lipoprotein Particle Clearance Chylomicron Remnant Clearance Low-density Lipoprotein Particle Clearance Cholesterol Homeostasis Viral Entry Into Host Cell Regulation Of Protein Metabolic Process Negative Regulation Of Protein Metabolic Process Membrane Organization Response To Caloric Restriction Negative Regulation Of Astrocyte Activation Cholesterol Import Cellular Response To Low-density Lipoprotein Particle Stimulus Receptor-mediated Endocytosis Involved In Cholesterol Transport Amyloid-beta Clearance Amyloid-beta Clearance By Cellular Catabolic Process Negative Regulation Of Microglial Cell Activation Positive Regulation Of Lysosomal Protein Catabolic Process Negative Regulation Of Amyloid Fibril Formation	Platelet Degranulation Inflammatory Response G Protein-coupled Receptor Signaling Pathway Adenylate Cyclase-activating G Protein-coupled Receptor Signaling Pathway Positive Regulation Of Gene Expression Positive Regulation Of Macrophage Derived Foam Cell Differentiation Negative Regulation Of Angiogenesis Cytokine-mediated Signaling Pathway Platelet Activation Neutrophil Chemotaxis Leukocyte Chemotaxis Positive Regulation Of Tumor Necrosis Factor Production Regulation Of Cell Population Proliferation Defense Response To Protozoan Negative Regulation Of MHC Class II Biosynthetic Process Positive Regulation Of Macrophage Differentiation Regulation Of Megakaryocyte Differentiation Negative Regulation Of Megakaryocyte Differentiation Positive Regulation Of Transcription By RNA Polymerase II Killing By Host Of Symbiont Cells Antimicrobial Humoral Immune Response Mediated By Antimicrobial Peptide Chemokine-mediated Signaling Pathway Cellular Response To Lipopolysaccharide Negative Regulation Of Extrinsic Apoptotic Signaling Pathway In Absence Of Ligand
Pathways		Cargo recognition for clathrin-mediated endocytosis Clathrin-mediated endocytosis Chylomicron clearance Chylomicron clearance LDL clearance Retinoid metabolism and transport	Platelet degranulation Common Pathway of Fibrin Clot Formation Cell surface interactions at the vascular wall Chemokine receptors bind chemokines G alpha (i) signalling events RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function
Drugs		Porfimer sodium	Drotrecogin alfa Heparin
Diseases		Hypercholesterolemia, autosomal dominant; Hyperlipoproteinemia, type IIa
GWAS		Abdominal aortic aneurysm ( 27899403 24046328) Apolipoprotein B levels ( 32203549) C-reactive protein levels or LDL-cholesterol levels (pleiotropy) ( 27286809) Cardiovascular disease risk factors ( 21943158) Carotid intima media thickness ( 21909108) Carotid plaque ( 30510157) Cholesterol ( 31902109) Cholesterol, total ( 24097068 19060911 25961943 20686565 26582766) Coronary artery disease ( 32469254 29212778 24262325 30104761 26343387 33020668) Coronary artery disease (myocardial infarction, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease) ( 28714975) Coronary artery disease or ischemic stroke ( 24262325) Coronary artery disease or large artery stroke ( 24262325) Coronary heart disease ( 21378990) Cortisol levels (saliva) ( 28843169) Disorders of lipid metabolism ( 30166351) HDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df) ( 30698716) Ischemic stroke ( 29531354) LDL cholesterol ( 23726366 24097068 18193043 18193044 20864672 19060906 19060910 19060911 30275531 21347282 25961943 20686565 26582766) LDL cholesterol levels ( 32203549 28334899 26690388 30698716) LDL cholesterol levels in current drinkers ( 30698716) LDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df) ( 30698716) LDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df) ( 30698716) LDL cholesterol levels x long total sleep time interaction (2df test) ( 31719535) LDL cholesterol levels x short total sleep time interaction (2df test) ( 31719535) Lipid metabolism phenotypes ( 22286219 19936222) Lipoprotein phospholipase A2 activity in cardiovascular disease ( 28753643) Lipoprotein-associated phospholipase A2 activity and mass ( 22003152) Low density lipoprotein cholesterol levels ( 30911093 29403010 31217584 31969989) Medication use (agents acting on the renin-angiotensin system) ( 31015401) Medication use (antithrombotic agents) ( 31015401) Medication use (HMG CoA reductase inhibitors) ( 31015401) Medication use (salicylic acid and derivatives) ( 31015401) Metabolite levels ( 21909109 23823483 22916037) Metabolite levels (lipoprotein measures) ( 27005778) Myocardial infarction ( 26343387) Myocardial infarction (early onset) ( 19198609) Parental lifespan ( 30642433) Parental longevity (combined parental attained age, Martingale residuals) ( 29227965) Peripheral artery disease ( 31285632) Response to statins (LDL cholesterol change) ( 31969989) Serum metabolite levels ( 31636271) Serum metabolite levels (CMS) ( 31636271) Stroke ( 29531354) Total cholesterol levels ( 28334899 30911093 29403010 31217584)	Inflammatory bowel disease ( 23128233) Metabolite levels ( 22916037) Serum metabolite levels ( 31636271) Serum metabolite levels (CMS) ( 31636271)
Interacting Genes		16 interacting genes: AP1M2 APOB APOE CD36 CREBBP DAB1 DAB2 HSPA5 LDLRAP1 LRPAP1 MAP4 MTIF3 PCSK9 PF4 SNX17 TLE5	28 interacting genes: CCL11 CCL13 CCL2 CCL20 CCL21 CCL25 CCL26 CCL28 CCL5 CXCL10 CXCL11 CXCL12 CXCL14 CXCL17 CXCL2 CXCL6 CXCL8 CXCL9 CXCR3 FGF2 LDLR PROC SDC2 SRGN THBD VCAN XCL1 XCL2
Entrez ID		3949	5196
HPRD ID		06091	01426
Ensembl ID		ENSG00000130164	ENSG00000163737
Uniprot IDs		A0A024R7D5 P01130	P02776
PDB IDs		1AJJ 1D2J 1F5Y 1F8Z 1HJ7 1HZ8 1I0U 1IJQ 1LDL 1LDR 1LRX 1N7D 1XFE 2FCW 2KRI 2LGP 2M7P 2MG9 2W2M 2W2N 2W2O 2W2P 2W2Q 3BPS 3GCW 3GCX 3M0C 3P5B 3P5C 3SO6 4NE9 5OY9 5OYL	1DN3 1F9Q 1F9R 1F9S 1PFM 1PFN 1RHP 4R9W 4R9Y 4RAU
Enriched GO Terms of Interacting Partners?
Tagcloud ?
Tagcloud (Difference) ?
Tagcloud (Intersection) ?